Question 1

What is Rigel Pharmaceuticals Inc. (New)'s WACC?

Accepted Answer

Rigel Pharmaceuticals Inc. (New) (RIGL) has a Weighted Average Cost of Capital (WACC) of 9.37%. This is calculated using a Cost of Equity of 9.26% (via CAPM with a beta of 1.26) and a pre-tax Cost of Debt of 13.20%, with an equity weight of 90.63% in the capital structure.

Question 2

Is Rigel Pharmaceuticals Inc. (New)'s WACC high or low?

Accepted Answer

Rigel Pharmaceuticals Inc. (New)'s WACC of 9.37% falls within the typical 8-12% range for mid-cap growth companies. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is Rigel Pharmaceuticals Inc. (New)'s WACC calculated?

Accepted Answer

Rigel Pharmaceuticals Inc. (New)'s WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 9.26% is derived from the CAPM model using a beta of 1.26. The pre-tax Cost of Debt (Rd) is 13.20%. The capital structure is 90.63% equity and 9.37% debt.

Rigel Pharmaceuticals Inc. (New) (RIGL) — WACC 分析

WACC 构成

解读

Rigel Pharmaceuticals Inc. (New)（RIGL）WACC：9.37%

WACC计算器

Rigel Pharmaceuticals Inc. (New)（RIGL） WACC 解读

RIGL 公司分析

RIGL DCF 估值

继续做同行对比